Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cidara Therapeutics ( (CDTX) ) has issued an update.
On June 18, 2025, Cidara Therapeutics held its Annual Meeting of Stockholders, where key amendments were approved. The stockholders agreed to increase the number of shares authorized under the 2024 Equity Incentive Plan by 2,880,000 shares and doubled the authorized shares of common stock from 50 million to 100 million. These changes are expected to enhance the company’s operational flexibility and support its growth strategy. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed.
The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.
Spark’s Take on CDTX Stock
According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.
Cidara Therapeutics’ overall stock score is primarily impacted by its challenging financial performance and valuation, with significant losses and reliance on external financing. Despite promising drug development updates, the company’s current lack of revenue generation and technical challenges further weigh down the score.
To see Spark’s full report on CDTX stock, click here.
More about Cidara Therapeutics
Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel anti-infectives and immunotherapies.
Average Trading Volume: 167,963
Technical Sentiment Signal: Buy
Current Market Cap: $276.4M
See more insights into CDTX stock on TipRanks’ Stock Analysis page.